Shorted
Radiopharm Theranostics logo
RAD

Radiopharm Theranostics

Pharmaceuticals, Biotechnology & Life Sciences

Radiopharm Theranostics is a clinical-stage radiotherapeutics company focused on developing a pipeline of first-in-class radiopharmaceuticals for the diagnosis and treatment of cancer. The company aims to transform cancer care by delivering innovative solutions for earlier detection and personalized treatment of cancers with unmet needs.

Short position

short percentage1.27%
reported shorts54.9M
shares on issue4.338B

Radiopharm Theranostics (ASX:RAD) has 1.27% of its shares on issue reported as short positions as of 16 Sept 2026, or about 54,932,710 shares. Over the past 30 days that figure has risen 1.25 percentage points, and over 90 days it has risen 1.22 percentage points. RAD is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.

Price & short interest

Toggle series, zoom, and compare · ASIC daily, T+4

Radiopharm Theranostics (RAD) News

Latest articles and price-sensitive announcements with AI sentiment classification.

Kalkine
Positive
5d ago

Radiopharm Theranostics (ASX: RAD) Completes Key FDA Meeting as RAD101 Enters Phase 3 Readiness

Highlights Radiopharm has completed its End-of-Phase 2 meeting with the FDA for RAD101s pivotal development program. Phase 2b data showed that RAD101 achieved 93% concordance with MRI across all evaluable lesions. The company begins Phase 3 readiness activities while awaiting formal FDA meeting minutes within approximately 30 days. Radiopharm is evaluating potential strategic partnerships as RAD101 progresses towards pivotal development. Radiopharm Theranostics Limited (ASX:RAD) has reached a...

Continue reading
Kalkine
Neutral
9 Sept

Radiopharm Theranostics (ASX:RAD) Eyes Phase 2 Study After Positive RAD301 Imaging Results

Highlights Radiopharm Theranostics reported positive Phase 1 imaging data for pancreatic cancer candidate RAD301. RAD301 demonstrated a favourable safety profile across all evaluable trial participants. Imaging showed significant and selective uptake in pancreatic cancer metastases. Low background uptake supported clearer distinction between lesions and surrounding normal tissue. Phase 1 findings provided a rationale for advancing RAD301 into Phase 2 development. Radiopharm Theranostics (ASX:...

Continue reading
Kalkine
Neutral
20 Aug

Radiopharm Theranostics (ASX:RAD) Gets DSMC Backing to Move RAD202 Into Cohort 4

Highlights Radiopharm has received a positive DSMC recommendation to advance RAD202 into Cohort 4 of the Phase 1 HEAT trial. The trial will now evaluate a higher 180mCi dose in patients with HER2-positive advanced solid tumours. The previous study dose level was 130mCi, announced in April 2026. An earlier diagnostic study in 10 HER2-positive breast cancer patients demonstrated clinical proof-of-concept, positive safety and biodistribution. Radiopharm Theranostics (ASX:RAD) (Nasdaq:RADX) has m...

Continue reading
Kalkine
Neutral
6 Aug

Clarity (ASX:CU6): What Puts Radiopharmaceutical Clinical Deliv in Focus?

Highlights Clarity is in focus after it released a biotechnology summit presentation in its latest update, creating a current test of evidence-led commercialisation. The Healthcare Stocks backdrop is shaped by clinical progress, regulatory pathways and channel expansion as Australia's market trades near record levels. The central operating question is radiopharmaceutical clinical delivery, with trial milestones, approvals, sales traction and cash use forming the evidence-based scorecard. Aust...

Continue reading
Kalkine
Neutral
3 Aug

Radiopharm (ASX:RAD) Expands Clinical Momentum with Positive Trial Updates

Highlights RAD 101 met its Phase 2b primary endpoint, with 93% of evaluable patients achieving concordance with MRI imaging in recurrent brain metastases. Radiopharm plans to commence a multi-centre, multi-country Phase 3 registrational trial for RAD 101 in Q4 2026. The first patient in the third dose cohort of the Phase 1 RAD 204 trial achieved a RECIST-confirmed partial response, with tumour shrinkage of up to 43% and progression-free survival exceeding seven months. The company continued adv...

Continue reading
Kalkine
Neutral
24 July

Radiopharm Theranostics (ASX:RAD) Raises AUD 12.5 Million to Advance Phase 3 Cancer Therapy Program

Highlights Radiopharm has secured firm commitments for an AUD 12.5 million institutional capital raising and launched a SPP targeting up to AUD 6 million. The proceeds will support the Phase 3 registrational study for RAD101, ongoing clinical development across multiple therapeutic programs, and strategic partnering initiatives. Investors have also committed up to AUD 3 million to cover any shortfall under the SPP, subject to shareholder approval. Radiopharm Theranostics (ASX:RAD) (Nasdaq:RA...

Continue reading
Kalkine
Neutral
24 July

Radiopharm Theranostics Secures A$18.5 Million to Propel Phase III-Ready Brain Imaging Agent RAD101

Radiopharm Theranostics Ltd (ASX: RAD), a clinical-stage radiopharmaceutical company specializing in oncology diagnostics and therapeutics, has successfully raised A$18.5 million through a A$12.5 million placement and a fully subscribed A$6.0 million share purchase plan. In July 2026, the company announced that its lead diagnostic candidate, RAD101—a first-in-class PET imaging agent for brain metastases—delivered a positive Phase IIb outcome, with 93% or more of patients meeting the primary ...

Continue reading
Kalkine
Neutral
24 July

Radiopharm Theranostics Secures A$12.5 Million Institutional Funding Ahead of RAD101 Phase 3 Trial Launch

Radiopharm Theranostics Limited (ASX: RAD, Nasdaq: RADX) has successfully raised approximately A$12.5 million in institutional funding, consisting of an A$6.7 million Australian placement and a concurrent US$4.1 million US Direct Registration Offering. The clinical-stage biopharmaceutical firm is also initiating a further A$6 million Share Purchase Plan (SPP) for eligible shareholders. The combined capital raise aims to finance preparations for the RAD101 registrational Phase 3 trial and support...

Continue reading
Kalkine
Neutral
24 July

Radiopharm Theranostics Initiates $10 Million Capital Raise with 800 Million Shares and Options Offering

Radiopharm Theranostics Limited (ASX: RAD) has unveiled a combined capital raising initiative that includes a securities purchase plan and a placement, aiming to secure up to A$10 million. The company plans to issue up to 400 million fully paid ordinary shares under the employee and shareholder purchase plan, along with 200 million options expiring on 31 July 2029 as part of a separate placement. The offer period concludes on 10 September 2026, with new shares anticipated to begin trading on 17 ...

Continue reading
Kalkine
Neutral
22 July

Imaging And Radiopharma Names Light Up Health Space

Highlights Medical imaging software and radiopharmaceutical developers have drawn fresh attention this stretch. These niches sit apart from the big exporters, offering a different flavour of health exposure. Global demand for smarter diagnostics and targeted therapies underpins their long-run stories. Not every corner of the health sector marches to the same beat as the giant exporters, and a cluster of specialist names has been quietly commanding attention on the Australian market. Pro Medic...

Continue reading
Kalkine
Neutral
8 July

Radiopharm Theranostics (ASX:RAD) Progresses Pipeline with Multiple Clinical Milestones

Highlights Radiopharm Theranostics is advancing multiple clinical-stage therapeutic and diagnostic programs across oncology indications. Lead candidate RAD204 has completed two Phase I dose cohorts, with tumour uptake confirmed in all treated participants and recruitment underway for the third cohort. RAD202, RAD402 and RV01 continue progressing through Phase I studies. The diagnostic candidate RAD101 reported ~90% concordance with MRI in its Phase 2b study and is prog...

Continue reading
Kalkine
Neutral
30 June

Radiopharm Theranostics (ASX:RAD): Why Are ASX Penny Stocks Facing a Catalyst Test?

Highlights Smaller ASX companies are being judged more closely on funding discipline and meaningful project milestones. Radiopharm Theranostics, Renascor Resources, Botanix Pharmaceuticals, Anson Resources and Dimerix highlight different parts of the sector. Cash runway, execution quality and catalyst delivery are becoming the key themes across the market. ASX penny stocks are facing a sharper c...

Continue reading